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A Primary Pathogen of Mammalian Hosts
Coccidioidomycosis is a potentially life-threatening respiratory
mycosis endemic to the Americas and caused by inhalation of
spores produced by the molds Coccidioides immitis and C. posadasii.
The dry, air-dispersed infectious spores (arthroconidia) are
derived from saprobic-phase filaments that grow in semidesert
soil of the southwestern United States and arid regions of Mexico
and Central and South America [1]. Coccidioides is a dimorphic
ascomycetous fungus with distinct saprobic and parasitic phases
and is classified in the order Onygenales together with other
genera of pathogenic molds that include Histoplasma, Blastomyces,
and Paracoccidioides. The clinical spectrum of disease caused by
these environmental pathogens ranges from a mild infection that
resolves spontaneously to a disseminated mycosis. Inhaled spores
of Coccidioides are small enough to colonize the lowermost reaches
of the respiratory tree. Nonhuman primates experimentally
challenged by aerosolization with fewer than ten infectious
propagules developed a severe form of the disease and died
within four to six weeks [2]. The parasitic cycle of Coccidioides is
unique among these medically important, dimorphic molds.
Spores in the lungs germinate to form multinucleate spherules
(.60 mm diameter) that are too large to be engulfed by host
phagocytes. The contents of mature spherules differentiate into a
multitude of propagative endospores. Production of indigestible
spherules that display high fecundity during the endosporulation
stage confound phagocytic defenses and augment survival of the
fungus in the lungs. Mammalian innate immune defenses are
further compromised by the ability of endosporulating spherules
to generate an alkaline microenvironment at infection sites due to
their release of ammonia, which contributes to the pathogen’s
virulence [3].
Need for a Vaccine
The incidence of symptomatic coccidioidomycosis in the United
States increased from 2,265 reported cases in 1998 to 22,401 in
2011 based on data from the National Notifiable Diseases
Surveillance System (NNDSS) [4]. This database likely underes-
timates the actual burden of disease. Reporting cases of Valley
Fever is not mandated in every state within known areas of
endemicity. Moreover, Coccidioides has established niches in
nontraditional endemic regions not considered in the report [5].
Approximately 10% of the total United States population resides
in the Southwest, including more than 300 thousand military
personnel who train in the semidesert terrain. Racial heritage (e.g.,
African and Filipino) influences susceptibility to this mycosis,
although the immunologic mechanism is unclear [6]. Millions of
tourists also visit popular landmarks in Texas, Arizona, and
southern California, and although many people are exposed to
Coccidioides spores, the majority (.60%) do not develop symptom-
atic disease. Nevertheless, a significant number of these individuals
are diagnosed with reactivated infection months to years after
returning home. Risk of infection is particularly high during dust
storms, which occur in the spring and summer in endemic regions
(http://directorsblog.health.azdhs.gov/?tag = valley-fever). A vac-
cine against coccidioidomycosis would arguably promote the
well-being of at-risk populations in the United States in addition
to people who reside in arid areas of Latin America. A
compelling argument for the feasibility of such a vaccine is
based on retrospective clinical evidence that individuals who
recover from symptomatic coccidioidal infection remain skin-test
positive and likely acquire life-long immunity to the disease. Both
clinical data and results of experimental animal studies have
shown that T-cell immunity is essential for protection against
coccidioidomycosis and mammalian hosts with deficiency of
CD4+ T cells are at elevated risk of contracting the respiratory
disease [7]. A vaccine development strategy must, therefore, be
designed to protect immunocompetent and as well as immuno-
compromised individuals. A formalin-killed spherule vaccine was
tested in a clinical trial between 1980 and 1985 and, although
there was a trend toward reduced disease, reactogenicity at sites
of immunization was too great, requiring the vaccine dose to be
reduced and thus underpowered [8]. Nevertheless, this early
pioneering study laid the foundation for current efforts to
generate a human vaccine.
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A Novel Adjuvant Enhances Cellular Immunity
Induced by a Live Vaccine
For many diseases in which natural infection confers
protective immunity against reinfection, live vaccines have been
successful in promoting robust and durable immune defenses in
humans. An attenuated mutant of Coccidioides was generated by
disruption of two chitinase genes that resulted in the inability of
the organism to endosporulate [9]. Inbred mice immunized
subcutaneously with the attenuated strain all survived after
intranasal challenge with a potentially lethal spore inoculum.
However, sterile immunity was not achieved and pulmonary
tissue damage associated with a persistent host inflammatory
response was evident, especially in BALB/c mice. Neutrophil
migration to infected lungs plays a pivotal role during the early
protective response [10], but persistence of these innate immune
cells in the presence of elevated inflammatory cytokines IL-1b,
IL-1a, and TNF-a leads to acute lung injury and disease
exacerbation. BALB/c and C57BL/6 mouse strains differ in
their ability to regulate inflammation associated with coccidioidal
lung infection, possibly simulating a clinical difference that partly
accounts for the heterogeneity of human immune responses to
coccidioidomycosis. Infected BALB/c mice that had been
immunized with the live, attenuated vaccine consistently
revealed 8-fold higher numbers of lung-infiltrated neutrophils
and significantly increased fungal burden compared to vaccinat-
ed C57BL/6 mice [9,11,12]. Thus, excessive inflammation due
to persistent high neutrophil counts appears to compromise
vaccine immunity.
We speculated that if the protracted recruitment of neutro-
phils to infection sites could be downregulated in BALB/c mice,
the outcome could be improved. We accomplished this using a
novel adjuvant conjugated with the live Coccidioides vaccine. A
decapeptide agonist of the biologically active C-terminal region
of human complement component C5a functions as an
adjuvant that enhances antigen processing by antigen presenting
cells (APCs) and promotes cellular immunity. Unique confor-
mational features of this agonist allow it to bind with high
affinity to C5a receptors (C5aR/CD88) on macrophages (MW)
and dendritic cells (DC) but not neutrophils [13]. The adjuvant,
termed EP67, was conjugated with lysine residues on the
surface of live arthroconidia from the vaccine strain [14]
(Figure 1A). Spore hydration and dilation steps physically
fractured the cysteine-rich, hydrophobic outer wall, permitting
EP67 conjugation with underlying cell wall components. EP67
directs the vaccine to C5aR-bearing MW and DC, inducing
phagocytosis and antigen presentation. BALB/c mice immu-
nized with the EP67-conjugated, live vaccine revealed increased
survival, reduction of inflammatory pathology, lower fungal
burden, and decreased recruitment of neutrophils to the lungs
at 11 days post-challenge compared to mice immunized with
the nonconjugated vaccine. The EP67 adjuvant enhanced
vaccine protection by augmenting T-cell immunity, especially
T-helper 1 (Th1) and Th17 responses [12]. Th17 immunity is
indispensable for protection against coccidioidomycosis [11].
Although not yet approved for use in humans, EP67 is a
promising adjuvant that drives relevant pathways of protective
immunity to Coccidioides infection. However, in spite of these
positive results, live vaccines are not ideal for immunocompro-
mised individuals at risk of severe reaction to the attenuated
strain, which highlights the need for safer and more efficacious
vaccines using purified antigens, appropriate adjuvants, and
efficient antigen delivery systems.
Figure 1. Novel adjuvant and vaccine delivery system for
enhancement of protective immunity to coccidioidomycosis.
(A) An agonist of human complement fragment C5a (EP67)
bound to live cells of an attenuated vaccine strain of
Coccidioides enhances T-cell immunity while downregulating
inflammatory pathology. Hydration and dilation of live arthroco-
nidia of the vaccine strain results in fracture of the hydrophobic outer
conidial wall and exposure of lysine residues of the underlying inner
wall that can conjugate with EP67 via S4BHyNic linkers (succinimidyl-4-
benzoylhydrazino-nicotinamide). The concept is that the engineered
conformational features of EP67 direct the conjugated vaccine to C5aR/
CD88 receptors on DC and MW, but not neutrophils, and activate
phagocytosis, antigen processing, and presentation by APCs while
dampening persistent neutrophil-associated inflammation at infection
sites [12,13]. (B) A glucan particle (GP)-based subunit vaccine
platform combines adjuvanicity with antigen delivery to
induce robust and durable CD4+ and CD8+ T-cell responses
to Coccidioides infection. GPs are composed of a porous shell and
hollow core. The protein vaccine is co-loaded with a carrier protein and
interacted with yeast RNA within the core to form an antigen complex
that is too large to diffuse out through the shell. Endo-Porter (EnP)
peptides added to the antigen matrix enhance release of the CD8+
vaccine proteins to the cytoplasm of APCs after phagocytosis of GPs
and promote processing and presentation of MHC I complexes,
resulting in activation of protective CD8+ T cells. Between the antigen
matrix and shell is a GP layer that can accommodate immune
modulators (e.g., CpG, siRNA) that help to elicit a protective response
to infection. Multiepitope constructs also may be coupled to the surface
of GPs by addition of a pyridyl-S-cysteine peptide at the N-terminus
(NPyr-Cys) of the vaccine protein. The C-terminus of GP surface-coupled
vaccine proteins may be conjugated with EP67 as in Figure 1A. EP67
directs the EBV to complement receptors and, although not yet tested,
may further enhance Th17 immunity. CD4+ and CD8+ multiepitope
vaccines are constructed using nonimmunogenic GPGPG or di-lysine
(KK) linkers [25,26]. b-1,3-glucans and opsonic C3 deposited on the
surface of GPs bind to Dectin-1 and complement receptors (CR),
respectively, and induce phagocytosis by APCs (MW and DC) followed
by antigen processing and peptide epitope display as MHC I or II
complexes [17,19].
doi:10.1371/journal.ppat.1003768.g001
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An Innovative Adjuvant and Delivery Platform
Contributes to the Protective Efficacy of
Alternative Subunit Vaccines
Although CD4+ T cells are central to the mammalian protective
response to Coccidioides infection, CD8+ T cells also mediate
vaccine immunity [15]. Recent studies of infections caused by
other dimorphic fungal pathogens have revealed that even in the
absence of CD4+ T-cell help vaccine-induced IL-17–producing
CD8+ T cells (Tc17) show long-term survival and confer
protection [16]. This plasticity of cellular immunity argues for
the feasibility of developing a vaccine against coccidioidomycosis
in patients with immune deficiencies, including those with few or
no CD4+ T cells. Our strategy in the design of a subunit vaccine
has been to generate polypeptide constructs containing multiple
immunodominant CD4+ or CD8+ T-cell epitopes that bind
promiscuously to human major histocompatibility complex class II
(MHC II) and MHC I molecules, respectively. T-cell epitopes
were initially predicted by immunoinformatic sequence analysis of
a selection of the many antigenic proteins of Coccidioides shown to
induce protection against coccidioidal lung infections in mice [17].
Immunoreactivity of synthetic epitope peptides was validated by
human MHC-specific binding assays and stimulation of immune
T-cells in vitro to produce protective Th1 and Th17 cytokines.
Epitope-based vaccines (EBV) against microbial diseases have
been shown to be immunologically potent, relatively easy to
produce, and are predicted to be safe in humans [18]. Bacterial-
expressed recombinant CD4+ and CD8+ T-cell epitopes joined by
nonimmunogenic linkers have been loaded into glucan particles
(GPs), which deliver the EBV to APCs and serve as a potent
adjuvant system [19] (Figure 1B). The selected epitopes are
conserved between C. immitis and C. posadasii [17]. GPs are
purified, hollow, porous shells made by alkali and acid extraction
of baker’s yeast, composed primarily of b-1,3-glucans, and
essentially devoid of proteins, lipids, and mannans. GPs activate
the alternative pathway of complement, leading to deposition of
C3 fragments. GPs are phagocytosed by MW and DC via
complement receptors and Dectin-1. Epitope-based vaccines
composed of CD4+ or CD8+ epitopes can either be loaded into
GPs or conjugated to the GP surface. EP67 conjugation with
epitope-based protein vaccines may provide an effective mecha-
nism to further augment Th17 immunity. CD8+ epitope–based
vaccines internalized by DC and presented as peptide-MHC class
I complexes can be enhanced by binding the EBV to a weak-base
amphiphilic peptide (Endo-Porter) that promotes antigen release
into the cytoplasm of APCs [20]. The GP core can accommodate
various adjuvant classes to fine-tune immune responses and
generate optimal and durable protection. The core of the loaded
GP forms a central antigen matrix with a surrounding layer that
accommodates immune modulators. For example, an oligodeox-
ynucleotide adjuvant (CpG) loaded into a GP-internalized, CD4+
epitope preparation and used to immunize mice against intranasal
infection significantly improved protection compared to the same
vaccine admixed with CpG in the absence of GPs [17]. Further,
Endo-Porter has been shown to form stable nanocomplexes with
small interfering RNAs (siRNAs), which when loaded into GPs
and delivered to phagocytic cells can downregulate proinflamma-
tory signaling and curb inflammatory pathology [21]. The glucan
particle delivery and adjuvant platform offers multiple options for
application of molecular tools that can optimally tailor a human
epitope-based vaccine against coccidioidomycosis. Corporate
partners currently evaluating the GP delivery technology are
planning to carry out prerequisite toxicology and safety studies
prior to the submission of an application for human testing.
Future Directions
Development of an effective coccidioidomycosis vaccine faces
several major challenges. Reported studies to date have assumed
that eliciting cell-mediated immunity will translate to protection
against the disease. However, the role of humoral response to
infection is still largely unexplored. It may be possible to protect
inbred mice with a vaccine that elicits cell-mediated immunity
alone, but we cannot assume that this observation will translate to
humans. A recent vector-based vaccine against tuberculosis
intended to protect by eliciting strong CMI failed in humans
despite showing efficacy in mice [22]. Most cases of coccidioido-
mycosis recorded in the United States occur in individuals over 60
years of age [4]. Vaccine development for the elderly must take
into account the aging immune system, a condition that may
increase vulnerability to infectious diseases [23]. A coccidioido-
mycosis vaccine potentiated by an adjuvant specifically designed to
stimulate the immune system of this demographic group (e.g.,
EP67) [24] is a current research priority.
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